Auto-generated from public data. Not the firm's stated position.
Based on disclosed data, i&i Biotech Fund appears to focus on early-stage biotech and drug discovery companies despite listed sector tags suggesting broader fintech and enterprise exposure. Recent portfolio companies indicate a concentration in therapeutic development and AI-enabled drug discovery, with check sizes ranging from €0.1M to €1.5M across pre-seed through Series B stages.
Generated 6 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from i&i Biotech Fund's website.
10+ years in venture capital and consulting with Ph.D. in Neuroscience leading drug development investments.
Venture capital and startup creation expert with Ph.D. in Immunology focused on innovative biotech and medtech.
PhD in Immunology; several years in venture capital, startup creation, and portfolio management.
25+ years in fund management and VC/PE with 100+ investments across CEE and the Baltics.
20+ years of leadership in life sciences, pharma, and diagnostics including CEO of Merck Czech subsidiary.
15+ years in fund management, VC, and PE with expertise in valuations, due diligence, and tax structuring.
15+ years in fund management, VC, and PE; expertise in valuations, due diligence, and tax structuring.
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.